Pfizer announced a multi-drug R&D collaboration with Innovent Biologics valued at $10.5 billion, targeting next-generation antibody-drug conjugates (ADCs) for targeted cancer therapies. The deal adds to a growing pattern of big pharma sourcing innovation from Chinese biotech platforms for ADC discovery and development. The collaboration’s focus on “next-generation” ADCs is notable as the class continues to expand beyond first-wave targets, with investors watching whether platform chemistry, payload strategy, and biomarker selection can sustain differentiation in a crowded oncology market. The structure and timeline details were not fully outlined in the summary available, but the headline figure underscores the perceived value of Innovent’s pipeline and manufacturing/development capabilities in ADC development—an area where speed and scalability are increasingly decisive.